Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Earnings Results, Misses Expectations By $0.03 EPS

Posted by Jessica Moore on Aug 7th, 2024

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) released its earnings results on Tuesday. The specialty pharmaceutical company reported $0.36 earnings per share for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03), Briefing.com reports. Supernus Pharmaceuticals had a negative net margin of 2.60% and a negative return on equity of 1.68%. The business had revenue of $168.30 million during the quarter, compared to the consensus estimate of $148.83 million. During the same period last year, the business posted ($0.02) EPS. The firm’s revenue for the quarter was up 24.1% on a year-over-year basis. Supernus Pharmaceuticals updated its FY 2024 guidance to EPS.

Supernus Pharmaceuticals Stock Up 14.8 %

Shares of NASDAQ:SUPN traded up $4.13 during midday trading on Wednesday, reaching $32.01. The company had a trading volume of 1,288,165 shares, compared to its average volume of 479,660. Supernus Pharmaceuticals has a 1-year low of $21.99 and a 1-year high of $35.44. The stock has a market cap of $1.76 billion, a PE ratio of -113.62 and a beta of 0.90. The business’s 50 day moving average price is $27.72 and its 200 day moving average price is $29.34.

Insider Activity at Supernus Pharmaceuticals

In related news, insider Tillotson Martin Tami 2,900 shares of the company’s stock in a transaction on Tuesday, July 30th. The was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 8.76% of the company’s stock.

About Supernus Pharmaceuticals

(Get Free Report)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.